Last reviewed · How we verify
NCT06570265
RES-SAFE (Resorption, Safety, and Efficacy of Absorbable Collagen Membrane)
NA trial testing GBR membrane in Guided Bone Regeneration in 50 participants. Not yet recruiting.
16 May 2026
Quick facts
| Lead sponsor | Hyundai Bioland Co., Ltd. |
|---|---|
| Phase | NA |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 50 |
| Start date | 16 December 2024 |
| Primary completion | 16 May 2026 |
| Estimated completion | 30 June 2026 |
Drugs / interventions tested
- GBR membrane
Conditions studied
- Guided Bone Regeneration — all drugs for Guided Bone Regeneration →
Sponsor
Hyundai Bioland Co., Ltd.
Who can join
18 and older, any sex, with Guided Bone Regeneration. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The clinical study aims to assess the long-term safety and efficacy of the interventional medical device. The clinical study will enrol up to 50 patients aged 18 years and older, who meet specific inclusion and exclusion criteria designed to ensure patient safety and reliable data collection.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06570265
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Guided Bone Regeneration
Currently open trials in the same condition.
- NCT07525128 — Lateral GBR Using Two Types of Membrane With a Combination of Allograft-xenograft · Phase 4 · active not recruiting
- NCT07526337 — Digital Planning and Clinical Assessment of the Treated Atrophic Posterior Maxilla With a Sinus Lift Procedure: a Cross- · recruiting
- NCT07367464 — Assessment Of Guided Bone Regeneration Using Xenograft Mixed With Allogenic Bone Graft Versus Xenograft Mixed With Autog · NA · recruiting
- NCT06295055 — Semi-rigid Shell Barrier System for Alveolar Bone Augmentation (SSBS for ABA) · NA · active not recruiting
Other Hyundai Bioland Co., Ltd. trials
Trials by the same sponsor.
- NCT04310215 — Efficacy and Safety of Allogenic Stem Cell Product(CARTISTEM®) for Osteochondral Lesion of Talus · Phase 3 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06570265 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hyundai Bioland Co., Ltd.
- Last refreshed: 26 August 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06570265.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing